List of Excipients in Branded Drug NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

Norethindrone, Ethinyl Estradiol and Ferrous Fumarate: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 16, 2026

The commercial value of norethindrone acetate/ethinyl estradiol and ferrous fumarate is concentrated in dosage-form execution rather than new-molecule exclusivity. The active hormonal combination is mature, genericized and subject to intense price competition. Attractive opportunities remain in chewable tablets, softgel capsules, taste masking, low-cost manufacturing, adherence-oriented packaging and differentiated distribution.

The product name requires technical precision. Most U.S. products described as norethindrone and ethinyl estradiol with ferrous fumarate contain norethindrone acetate, not unconjugated norethindrone. The common strength is norethindrone acetate 1 mg plus ethinyl estradiol 20 micrograms, followed by four ferrous fumarate tablets in a 24/4 regimen. Product-specific composition must be verified against the FDA-approved labeling and Drug Listing data.

What products contain norethindrone acetate, ethinyl estradiol and ferrous fumarate?

The principal U.S. dosage forms are 28-day oral contraceptive packs containing 24 hormonal tablets or capsules and four ferrous fumarate tablets or capsules.

Product or product type	Hormonal component	Iron component	Dosage form	Commercial significance
Loestrin 24 Fe-type product	Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg	Ferrous fumarate, commonly 75 mg per tablet	Oral tablet	Reference-product lineage for multiple generics
Minastrin 24 Fe-type product	Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg	Ferrous fumarate placebo capsules	Chewable tablet plus capsule	Taste, mechanical strength and packaging matter
Taytulla-type product	Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg	Ferrous fumarate placebo capsules	Softgel capsule	Softgel manufacturing and capsule stability create entry barriers
Generic combination products	Usually equivalent hormonal strength	Ferrous fumarate in the inactive treatment interval	Tablet, chewable or capsule, depending on ANDA	Price-led competition with limited room for undifferentiated products

The ferrous fumarate units are generally intended to maintain the daily dosing schedule. They do not convert the product into an anemia treatment. The prescribing information states that the iron tablets are nonhormonal and that patients should not rely on them to treat iron-deficiency anemia.[1]

What is the FDA regulatory status of the combination?

The products are prescription combined hormonal contraceptives regulated through new drug applications and abbreviated new drug applications. Generic manufacturers generally pursue the 505(j) ANDA pathway under the Federal Food, Drug, and Cosmetic Act.[2]

The FDA review focuses on:

• Pharmaceutical equivalence of the hormonal units.
• Bioequivalence to the reference product.
• Assay and content uniformity for low-dose ethinyl estradiol.
• Dissolution and release behavior.
• Stability of the hormonal actives and ferrous fumarate.
• Container-closure performance.
• Labeling consistency.
• Demonstration that the dosage form can be used according to the 24/4 regimen.

The product is not a biologic and has no biosimilar pathway. Biosimilar risk is therefore not relevant. The competitive threat comes from ANDA applicants, authorized generics, brand extensions and private-label supply agreements.

The FDA Orange Book remains the controlling source for current reference products, patents, exclusivity codes and therapeutic-equivalence listings. Orange Book entries can change through patent-listing updates, delistings, pediatric-exclusivity events and FDA administrative actions.[3]

When does norethindrone acetate and ethinyl estradiol lose exclusivity?

The underlying hormonal combination has lost practical market exclusivity in the United States. The commercial question is no longer whether the molecule is protected, but whether a specific dosage form has residual formulation, use, device or manufacturing protection.

A product-level exclusivity review should separate four categories:

Protection category	Relevance to this combination
New chemical entity exclusivity	Generally not available for this mature hormonal combination
Five-year NCE exclusivity	Not applicable to a genericized norethindrone acetate/ethinyl estradiol product
Three-year clinical-investigation exclusivity	May apply only to qualifying new applications or changes, not automatically to every generic product
Patent protection	May remain relevant for a specific chewable, softgel, release profile, composition or manufacturing process

The reference product’s market position can persist after basic patent expiry because of physician familiarity, pharmacy substitution rules, supply reliability and residual brand loyalty. That commercial durability is different from statutory exclusivity.

Exact patent expiration dates should be taken from the current Orange Book patent table and the relevant patent records. Historical patents associated with early Loestrin, Minastrin and related products may have expired, been disclaimed, been delisted or become commercially irrelevant. A historical patent number without current Orange Book and prosecution-status verification is not a reliable basis for launch planning.

What patents protect these contraceptive products?

The strongest potential patent positions are formulation and dosage-form claims rather than composition-of-matter claims covering the hormones.

Formulation patents

Potential claim areas include:

• A chewable tablet containing norethindrone acetate and ethinyl estradiol.
• A dosage form with a specified hardness or friability profile.
• Taste-masking systems for ethinyl estradiol or norethindrone acetate.
• A softgel shell containing the hormonal suspension or solution.
• Specific solvent, surfactant or suspension systems.
• A 24 active/4 ferrous fumarate regimen.
• A composition that maintains potency during storage.
• Reduced degradation of ethinyl estradiol.
• Specified dissolution characteristics.
• A capsule or tablet with improved swallowability or palatability.

Method-of-use patents

Potential use claims may concern:

• A 24-day hormonal regimen followed by four nonhormonal dosage units.
• Contraceptive use in a defined patient population.
• Reduction of hormone-free interval exposure.
• Management of scheduled withdrawal bleeding.
• Treatment of acne or other hormone-responsive conditions, where supported by the approved label.

Method-of-use patents are less powerful when the same active ingredients and regimen have long been used for contraception. Their practical value depends on claim scope, Orange Book listing, enforceability and whether a generic applicant can submit a Paragraph IV certification or a section viii statement.

Manufacturing patents

Manufacturing claims may cover:

• Wet or dry granulation.
• Low-dose API blending.
• Hormone layering or coating.
• Softgel fill preparation.
• Encapsulation conditions.
• Iron-tablet manufacture.
• Moisture-control systems.
• Packaging that limits light or oxygen exposure.

Process patents often have less leverage against a finished-dose competitor unless infringement can be established from the marketed product or through discovery. They can still raise supply-chain and technology-transfer barriers in licensing transactions.

How important are excipients in this product category?

Excipients determine whether a technically equivalent product is commercially usable. The hormonal doses are small, and the dosage form must deliver reproducible content while remaining stable, manufacturable and acceptable to patients.

Active hormonal tablets

A conventional immediate-release tablet may use:

• Microcrystalline cellulose as a diluent and compressibility aid.
• Lactose or other fillers, subject to compatibility and labeling requirements.
• Crospovidone, croscarmellose sodium or sodium starch glycolate as disintegrants.
• Povidone or hydroxypropyl cellulose as binders.
• Magnesium stearate or comparable lubricants.
• Colloidal silicon dioxide as a glidant.
• Film-coating polymers, plasticizers and colorants.

The principal technical challenge is not high drug loading. It is uniform distribution of microgram quantities of ethinyl estradiol across the blend. Segregation, adhesion to manufacturing equipment and API particle-size variation can produce assay and content-uniformity failures.

Chewable dosage forms

Chewable products offer a clear commercial differentiation route, but excipient selection becomes more demanding. The formulation must balance:

• Acceptable taste.
• Rapid disintegration.
• Sufficient tablet strength.
• Low friability during packaging and shipment.
• Minimal grittiness.
• Low moisture uptake.
• Consistent flavor release.
• No unacceptable interaction with the hormone APIs.

Mannitol, sorbitol, xylitol, compressible sugars and co-processed excipients can improve mouthfeel. Polyols can create hygroscopicity and gastrointestinal tolerability issues. Sweeteners and flavors may mask bitterness but can complicate stability and regulatory comparability.

A generic chewable product must demonstrate pharmaceutical equivalence and bioequivalence while preserving the intended use characteristics. A chewable product that behaves like a conventional swallowed tablet may face physician, pharmacist or patient acceptance problems even if it meets laboratory specifications.

Softgel capsules

Softgels create a different formulation platform. Typical development variables include:

• Oil or lipid-based fill systems.
• Cosolvents and surfactants.
• Suspending agents.
• Gelatin or non-gelatin shell composition.
• Shell plasticizer level.
• Water migration between fill and shell.
• Oxygen and light protection.
• Capsule sealing and leakage control.

Softgels can improve swallowability and support product differentiation. They require specialized equipment, higher process-control capability and more demanding stability programs. Shell cross-linking, fill migration and long-term leakage are commercial risks. A manufacturer with established softgel capacity has an advantage over a conventional tablet producer entering the category.

Ferrous fumarate units

The ferrous fumarate units can use standard direct-compression or granulation excipients. Important factors include:

• Iron-related discoloration.
• Metallic taste and odor.
• Abrasion of tooling.
• Tablet hardness.
• Moisture sensitivity.
• Cross-contamination controls.
• Visual differentiation from hormonal units.

The iron units should be clearly distinguished through color, shape, imprint or packaging. Mix-ups within a 28-day pack create a medication-use risk and can generate recalls or product-liability exposure.

What excipient strategies create commercial differentiation?

The most credible strategy is to build around a specific patient or channel problem rather than change excipients without a use case.

Strategy	Patient or commercial benefit	Main development risk
Low-force chewable tablet	Easier administration for patients who dislike swallowing pills	Taste, friability and content uniformity
Sugar-free chewable	Suitable for sugar-conscious users	Palatability and polyol tolerability
Lactose-free formulation	Expands use among lactose-sensitive patients	Replacement excipient compatibility
Small-format tablet or capsule	Improves swallowability	Limited formulation space
Moisture-resistant blister pack	Protects stability and unit-dose adherence	Higher packaging cost
Calendarized 28-day pack	Reduces missed doses	Packaging complexity
Color-coded hormonal and iron units	Lowers dosing confusion	Manufacturing and artwork controls
Private-label softgel	Supports pharmacy, telehealth or employer channels	Softgel capital and supply continuity

Excipients should not be positioned as clinically superior without supporting comparative evidence. A better commercial claim is often operational: easier swallowing, improved pack usability, lower storage sensitivity or more consistent supply.

What generic entry risks exist for the combination?

Generic entry risk is high for conventional tablets and moderate for differentiated dosage forms.

A standard tablet competitor faces:

• Multiple potential ANDA applicants.
• Low switching costs.
• Pharmacy substitution.
• Limited prescriber attachment.
• High price pressure.
• Contract-manufacturing competition.

A chewable or softgel competitor faces a narrower field because development requires more specialized technology. The risk then shifts from patent barriers to regulatory comparability, manufacturing reliability and market access.

Paragraph IV challenges can arise when an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable or will not be infringed. The reference sponsor may file suit within the statutory period, triggering a 30-month stay of approval under applicable conditions.[4] A section viii statement may be used when the applicant seeks approval without the patented method of use, provided the labeling and product design support that position.

For this class, the most important Paragraph IV targets would be:

• Chewable composition claims.
• Softgel fill and shell claims.
• Regimen claims.
• Stability or packaging claims listed in the Orange Book.
• Later-issued formulation patents attached to an approved product.

The litigation risk is lower when the target product has only expired active-ingredient patents and no enforceable listed formulation claims.

What patent litigation and settlement issues affect market entry?

The commercial impact of litigation depends on whether the patent covers the marketed dosage form or only a narrow manufacturing process. Settlement agreements can establish:

• A fixed generic launch date.
• An authorized-generic arrangement.
• A license restricted by channel or geography.
• Supply obligations.
• A no-challenge provision.
• Volume or royalty terms.

For a mature oral contraceptive, a licensed early-entry agreement may be more valuable than prolonged litigation. The market has several substitutable products, so a delayed launch can reduce the value of exclusivity unless the product has a strong formulation distinction or channel position.

The FTC reviews pharmaceutical patent settlements for potential anticompetitive provisions. Any transaction involving a brand sponsor, first filer, authorized generic or launch restriction requires review of the agreement’s payment, supply and timing terms.[5]

How strong is the patent estate for norethindrone acetate and ethinyl estradiol products?

The patent estate is generally weak for the active ingredients and stronger, where applicable, for specialized dosage forms.

Estate component	Relative strength	Business implication
Hormonal composition	Low	Does not support durable exclusivity
Conventional immediate-release tablet	Low to moderate	Commodity generic exposure
24/4 regimen	Moderate only if claim scope is specific and enforceable	Often vulnerable to design-around or labeling strategies
Chewable formulation	Moderate	Can delay or complicate direct substitution
Softgel formulation	Moderate to strong	Technical manufacturing barriers may limit competitors
Taste masking	Moderate	Value depends on claim breadth and measurable performance
Packaging and adherence system	Low to moderate	Useful for differentiation, less useful against all generic entry
Manufacturing process	Variable	Can protect know-how and supply, but infringement may be difficult to prove

The practical moat is often a combination of formulation know-how, regulatory files, process capability, packaging control and commercial execution. Patent ownership alone is unlikely to support a high valuation for an undifferentiated product.

What licensing and partnership opportunities exist?

Potential partners include:

• Generic manufacturers with established hormone-product facilities.
• Softgel specialists.
• Contract development and manufacturing organizations.
• Telehealth contraception platforms.
• Pharmacy chains and private-label operators.
• International distributors.
• Companies with established women's-health sales forces.

The most financeable licensing assets are:

1. A validated chewable platform with acceptable taste and bioequivalence.
2. A softgel formulation with strong stability and scalable encapsulation.
3. A low-cost, lactose-free or sugar-free formulation.
4. A packaging system that supports adherence and reduces medication errors.
5. A regional dossier with approved or near-approved regulatory status.
6. A manufacturing process that reduces batch failure or improves yield.

Licensing value should be based on contribution margin, launch timing, manufacturing capacity and competitive intensity. A formulation patent without demonstrated manufacturability has limited transaction value.

How does this product compare with other combined oral contraceptives?

The norethindrone acetate/ethinyl estradiol and ferrous fumarate combination competes primarily on tolerability, regimen familiarity, dosage-form convenience and price.

Product characteristic	Norethindrone acetate/EE/ferrous fumarate	Drospirenone/EE products	Levonorgestrel/EE products
Progestin class	Norethindrone acetate	Drospirenone	Levonorgestrel
Ferrous fumarate interval units	Common in 24/4 products	Product-dependent	Less central to the category
Generic competition	High	High, with some product-specific complexity	Very high
Differentiation opportunity	Chewable, softgel, packaging	Formulation and indication positioning	Cost and supply
Key commercial constraint	Commodity pricing	Product-specific safety and labeling considerations	Heavy generic competition

A new product needs a defined advantage over low-cost conventional generics. Excipient differentiation is most credible when it improves administration or supply economics without creating a difficult bioequivalence pathway.

What is the revenue exposure and commercial outlook?

Revenue exposure is concentrated in prescription contraceptive volume, not iron sales. The four ferrous fumarate units add little intrinsic revenue value. They increase packaging, tablet-control and supply-chain requirements.

The strongest commercial models are:

• High-volume, low-cost generic supply.
• Authorized generic manufacturing.
• Private-label pharmacy products.
• Chewable products with a premium to standard generics.
• Softgel products in telehealth and direct-to-consumer channels.
• Regional licensing where branded products remain less commoditized.
• Dual-source supply contracts that reduce pharmacy stock-out risk.

The weakest model is an undifferentiated conventional tablet launched into a crowded generic market without cost leadership, supply reliability or a channel agreement.

Key Takeaways

• The likely active hormonal ingredients are norethindrone acetate 1 mg and ethinyl estradiol 20 micrograms, followed by four ferrous fumarate units.
• The hormones are mature, genericized ingredients with limited composition-of-matter value.
• Commercial protection is more likely to come from chewable, softgel, taste-masked, packaging or manufacturing technology.
• The FDA 505(j) ANDA pathway is the principal generic route.
• Biosimilar risk does not apply because the product is a small-molecule oral contraceptive.
• Paragraph IV risk depends on current Orange Book-listed patents, not historical patent associations.
• Ferrous fumarate is primarily a regimen and adherence component, not a major revenue driver.
• Softgel and chewable platforms offer the strongest formulation-led opportunities.
• Conventional tablets face high generic-entry and price-erosion risk.
• A licensing transaction is most attractive when it includes validated bioequivalence, scalable manufacturing and protected distribution.

Frequently Asked Questions

Is ferrous fumarate therapeutically necessary in this contraceptive pack?

No. It generally occupies the four nonhormonal days and helps preserve a daily dosing routine. It should not be marketed as an anemia treatment without separate clinical and regulatory support.[1]

Can a generic omit the ferrous fumarate tablets?

A product seeking therapeutic equivalence to a reference 24/4 product must comply with applicable FDA requirements for the dosage regimen and labeling. Omitting or materially changing the nonhormonal units may affect pharmaceutical equivalence, labeling and substitutability.

Are chewable contraceptive tablets protected by separate patents?

They may be. Protection can cover the chewable composition, taste masking, mechanical properties, dissolution behavior or manufacturing process. Current Orange Book listings and patent claims determine whether those rights remain relevant.

Does a lactose-free formulation create regulatory exclusivity?

No. Lactose-free status is a formulation and marketing distinction. It may support patient targeting or private-label positioning, but it does not automatically create FDA exclusivity or patent protection.

What is the best commercial entry strategy?

For a new entrant, the strongest options are a validated chewable or softgel product, a low-cost private-label supply model, or a differentiated pack with reliable pharmacy and telehealth distribution. A standard tablet requires a structural cost or supply advantage.

References

1. U.S. Food and Drug Administration. (n.d.). Norethindrone acetate and ethinyl estradiol and ferrous fumarate prescribing information. FDA-approved product labeling.

2. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Congress. (2024). Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

5. Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act. FTC.